Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida. Show more

501 E. Las Olas Blvd., Fort Lauderdale, FL, 33301, United States

Biotechnology

Healthcare

Market Cap

3.836M

52 Wk Range

$1.50 - $4.59

Previous Close

$1.56

Open

$1.52

Volume

18,275

Day Range

$1.50 - $1.53

Enterprise Value

3.712M

Cash

124K

Avg Qtr Burn

-300K

Insider Ownership

15.30%

Institutional Own.

4.88%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TCR-T targeting neoantigens Details Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.